35 results on '"Delahunt, B."'
Search Results
2. Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour
- Author
-
Delahunt, B, Eble, J N, King, D, Bethwaite, P B, Nacey, J N, and Thornton, A
- Published
- 2000
3. Diffuse malignant mesothelioma arising in a paracolostomy hernial sac
- Author
-
BETHWAITE, P. B., EVANS, R., NAIK, D. K., DELAHUNT, B., and TEAGUE, C. A.
- Published
- 1996
4. Aortic aneurysm in systemic lupus erythematosus
- Author
-
STEHBENS, W.E., primary, DELAHUNT, B., additional, SHIRER, W.C., additional, and NAIK, D.K., additional
- Published
- 1993
- Full Text
- View/download PDF
5. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria.
- Author
-
Egevad L, Delahunt B, Iczkowski KA, van der Kwast T, van Leenders GJLH, Leite KRM, Pan CC, Samaratunga H, Tsuzuki T, Mulliqi N, Ji X, Olsson H, Valkonen M, Ruusuvuori P, Eklund M, and Kartasalo K
- Subjects
- Male, Humans, Prostate pathology, Reproducibility of Results, Biopsy, Needle, Biopsy, Neoplasm Grading, Adenocarcinoma diagnosis, Adenocarcinoma pathology, Prostatic Neoplasms diagnosis, Prostatic Neoplasms pathology
- Abstract
Aims: There is strong evidence that cribriform morphology indicates a worse prognosis of prostatic adenocarcinoma. Our aim was to investigate its interobserver reproducibility in prostate needle biopsies., Methods and Results: A panel of nine prostate pathology experts from five continents independently reviewed 304 digitised biopsies for cribriform cancer according to recent International Society of Urological Pathology criteria. The biopsies were collected from a series of 702 biopsies that were reviewed by one of the panellists for enrichment of high-grade cancer and potentially cribriform structures. A 2/3 consensus diagnosis of cribriform and noncribriform cancer was reached in 90% (272/304) of the biopsies with a mean kappa value of 0.56 (95% confidence interval 0.52-0.61). The prevalence of consensus cribriform cancers was estimated to 4%, 12%, 21%, and 20% of Gleason scores 7 (3 + 4), 7 (4 + 3), 8, and 9-10, respectively. More than two cribriform structures per level or a largest cribriform mass with ≥9 lumina or a diameter of ≥0.5 mm predicted a consensus diagnosis of cribriform cancer in 88% (70/80), 84% (87/103), and 90% (56/62), respectively, and noncribriform cancer in 3% (2/80), 5% (5/103), and 2% (1/62), respectively (all P < 0.01)., Conclusion: Cribriform prostate cancer was seen in a minority of needle biopsies with high-grade cancer. Stringent diagnostic criteria enabled the identification of cribriform patterns and the generation of a large set of consensus cases for standardisation., (© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
6. Intraductal carcinoma of the prostate is not a diagnostic entity.
- Author
-
Delahunt B, Egevad L, Samaratunga H, Srigley JR, Cheng L, Clouston D, Furusato B, Kench J, Leite KRM, MacLennan GT, Moch H, Pan CC, Ro J, Tsuzuki T, van der Kwast T, Wheeler T, and Yaxley JW
- Subjects
- Humans, Male, Adenocarcinoma, Carcinoma, Intraductal, Noninfiltrating diagnosis, Prostatic Neoplasms diagnosis
- Published
- 2021
- Full Text
- View/download PDF
7. Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial.
- Author
-
Delahunt B, Murray JD, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Matthews J, Oldmeadow C, Samaratunga H, Spry NA, Srigley JR, Hondermarck H, and Denham JW
- Subjects
- Adenocarcinoma complications, Aged, Biopsy, Needle, Bone Neoplasms etiology, Bone Neoplasms pathology, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness pathology, Neoplasm Metastasis pathology, Prognosis, Prostate pathology, Prostate-Specific Antigen, Prostatic Neoplasms complications, Adenocarcinoma pathology, Peripheral Nerves pathology, Prostatic Neoplasms pathology
- Abstract
Aims: Perineural invasion (PNI) by prostatic adenocarcinoma is debated as a prognostic parameter. This study investigates the prognostic predictive value of PNI in a series of patients with locally advanced prostate cancer treated with radiotherapy and androgen deprivation using 10 years outcome data from the TROG 03.04 RADAR trial., Methods: Diagnostic prostate biopsies from 976 patients were reviewed and the presence of PNI noted. Patients were followed for 10 years according to the trial protocol or until death. The primary endpoint for the study was time to bone metastasis. Secondary endpoints included time to soft tissue metastasis, transition to castration resistance, prostate cancer-specific mortality and all-cause mortality., Results: PNI was detected in 449 cases (46%), with 234 cases (24%) having PNI in more than one core. The presence of PNI was significantly associated with higher ISUP grade, clinical T staging category, National Comprehensive Cancer Network risk group, and percent positive biopsy cores. The cumulative probability of bone metastases according to PNI status was significant over the 10 years follow-up interval of the study (log-rank test P < 0.0001). PNI was associated with all endpoints on univariable analysis. After adjusting for baseline clinicopathological and treatment factors, bone metastasis was the only endpoint in which PNI retained its prognostic significance (hazard ratio 1.42, 95% confidence interval 1.05-1.92, P = 0.021)., Conclusions: The association between PNI and the development of bone metastases supports the inclusion of this parameter as a component of the routine histology report. Further this association suggests that evaluation of PNI may assist in selecting those patients who should be monitored more closely during follow-up., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
8. Macroscopy under the microscope: a critical reappraisal of grossing techniques.
- Author
-
Varma M, Delahunt B, McCluggage WG, Shah VI, and Berney DM
- Subjects
- Humans, Pathology, Surgical methods, Specimen Handling methods
- Published
- 2020
- Full Text
- View/download PDF
9. The utility of artificial intelligence in the assessment of prostate pathology.
- Author
-
Egevad L, Ström P, Kartasalo K, Olsson H, Samaratunga H, Delahunt B, and Eklund M
- Subjects
- Biopsy, Needle, Humans, Male, Neoplasm Grading methods, Prostatic Neoplasms pathology, Artificial Intelligence, Prostate pathology, Prostatic Neoplasms diagnosis
- Published
- 2020
- Full Text
- View/download PDF
10. Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR).
- Author
-
Shanks JH, Srigley JR, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter VE, Samaratunga H, Tsuzuki T, van der Kwast T, Varma M, and Grignon D
- Subjects
- Humans, Pathology, Clinical methods, Research Design standards, Carcinoma, Datasets as Topic, Pathology, Clinical standards, Urethral Neoplasms
- Abstract
The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit organisation sponsored by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists in association with the Canadian Partnership Against Cancer, the European Society of Pathology, the American Society of Clinical Pathology and the Faculty of Pathology, Royal College of Physicians of Ireland. Its goal is to produce standardised, internationally agreed-upon, evidence-based datasets for cancer pathology reporting throughout the world. This paper describes the development of a cancer dataset by the multidisciplinary ICCR expert panel for the reporting of carcinoma of the urethra in urethrectomy specimens. The dataset is composed of 'required' (mandatory) and 'recommended' (non-mandatory) elements, which are based on a review of the most recent evidence and supported by explanatory commentary. Fourteen required elements and eight recommended elements were agreed by the international dataset authoring committee to represent the essential/required (core) and recommended (non-core) information for the reporting of carcinoma of the urethra in urethrectomy specimens. Use of an internationally agreed, structured pathology dataset for reporting carcinoma of the urethra (in urethrectomy specimens) will provide the necessary information for optimal patient management, will facilitate consistent data collection and will provide valuable data for research and international benchmarking. The dataset will be valuable for those countries and institutions that are not in a position to develop their own datasets., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
11. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR).
- Author
-
Delahunt B, Srigley JR, Judge MJ, Amin MB, Billis A, Camparo P, Evans AJ, Fleming S, Griffiths DF, Lopez-Beltran A, Martignoni G, Moch H, Nacey JN, and Zhou M
- Subjects
- Australasia, Humans, Pathology, Clinical methods, Pathology, Clinical standards, Carcinoma, Renal Cell, Datasets as Topic standards, Kidney Neoplasms, Research Design standards
- Abstract
Aims: The International Collaboration on Cancer Reporting (ICCR) has provided detailed data sets based upon the published reporting protocols of the Royal College of Pathologists, the Royal College of Pathologists of Australasia and the College of American Pathologists., Methods and Results: The data set for carcinomas of renal tubular origin treated by nephrectomy was developed to provide a minimum structured reporting template suitable for international use, and incorporated recommendations from the 2012 Vancouver Consensus Conference of the International Society of Urological Pathology (ISUP) and the fourth edition of the World Health Organisation Bluebook on tumours of the urinary and male genital systems published in 2016. Reporting elements were divided into those, which are required and recommended components of the report. Required elements are: specimen laterality, operative procedure, attached structures, tumour focality, tumour dimension, tumour type, WHO/ISUP grade, sarcomatoid/rhabdoid morphology, tumour necrosis, extent of invasion, lymph node status, surgical margin status, AJCC TNM staging and co-existing pathology. Recommended reporting elements are: pre-operative treatment, details of tissue removed for experimental purposes prior to submission, site of tumour(s) block identification key, extent of sarcomatoid and/or rhabdoid component, extent of necrosis, presence of tumour in renal vein wall, lymphovascular invasion and lymph node status (size of largest focus and extranodal extension)., Conclusions: It is anticipated that the implementation of this data set in routine clinical practice will inform patient treatment as well as provide standardised information relating to outcome prediction. The harmonisation of data reporting should also facilitate international research collaborations., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
12. Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma.
- Author
-
Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, and Samaratunga H
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell surgery, Female, Humans, Kidney Neoplasms surgery, Male, Middle Aged, Necrosis pathology, Neoplasm Grading, Nephrectomy, Prognosis, Treatment Outcome, World Health Organization, Carcinoma, Renal Cell pathology, Kidney pathology, Kidney Neoplasms pathology
- Abstract
Aims: The aims of this study were to evaluate the impact of tumour-associated necrosis (TAN) on metastasis-free survival for clear cell renal cell carcinoma (RCC), and to determine whether TAN provides survival information additional to World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading., Methods and Results: The study consisted of 376 cases of clear cell RCC treated by nephrectomy, for which follow-up was available. WHO/ISUP grade was assigned, and sections were assessed for the presence of TAN. American Joint Committee on Cancer (AJCC) pT staging category and tumour size were also recorded. The development of metastatic disease was taken as the clinical endpoint, and survival analyses, utilising univariate and multivariate models, were performed. WHO/ISUP grades were: grade 1, 35 cases (9.3%); grade 2, 188 cases (50.0%); grade 3, 91 cases (24.2%); and grade 4, 62 cases (16.5%). Staging categories were pT1-pT2 [234 tumours (62.2%)] and pT3-pT4 [139 tumours (37.0%)]. TAN was seen in 128 cases (34.0%). Neither TAN nor metastases were seen in grade 1 tumours. Among grade 2-4 tumours, those with TAN had a significantly worse prognosis than those without TAN (P = 0.017, P = 0.04, and P = 0.006, respectively). Multivariate analysis (WHO/ISUP grade, pT staging category, and TAN) showed all three variables to be independently associated with outcome (P = 0.009, P = 0.005, and P = 0.001, respectively). For all tumour grades and pT staging categories, it was found that the presence of TAN was associated with a 2.91-fold greater risk of metastatic disease., Conclusion: Tumour-associated necrosis is an important prognostic factor for clear cell RCC, independently of WHO/ISUP grade. This supports the suggestion that TAN could be incorporated into tumour grading criteria., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
13. Grading of renal cell carcinoma.
- Author
-
Delahunt B, Eble JN, Egevad L, and Samaratunga H
- Subjects
- Humans, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology, Neoplasm Grading methods
- Abstract
Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. Numerous grading systems have been proposed, initially focusing upon a constellation of cytological features and more recently on nuclear morphology. It has been recommended that grading of RCC should be based upon nucleolar prominence/eosinophilia for grades 1-3, while grade 4 requires nuclear anaplasia (including tumour giant cells, sarcomatoid differentiation and/or rhabdoid morphology). The grading system was adopted formally by the International Society of Urological Pathology (ISUP) and subsequently by the World Health Organisation (WHO), being designated the WHO/ISUP grading classification in the fourth edition of the WHO classification tumours of the urinary system and male genital organs (2016). This grading system has been validated for both clear cell and papillary RCC. Validation studies for chromophobe RCC failed to demonstrate a correlation between grade and outcome for both the superseded Fuhrman grading system and the WHO/ISUP grading classification, and it has been recommended that these tumours not be graded. The WHO/ISUP system has been incorporated into the structured reports of the International Cancer Collaboration on Cancer Reporting for both clear cell and papillary RCC. It is also noted that other types of RCC may be graded, but it must be emphasised in the report that this is for descriptive and diagnostic purposes, and not outcome prediction. More recent studies have shown the incorporation of the presence of tumour necrosis into RCC grading to improve outcome prediction, and this has been validated in several studies., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
14. Re: Comment on Egevad et al., 'Utility of Pathology Imagebase for standardisation of prostate cancer grading'.
- Author
-
Egevad L, Samaratunga H, and Delahunt B
- Subjects
- Humans, Male, Reference Standards, Neoplasm Grading, Prostatic Neoplasms
- Published
- 2018
- Full Text
- View/download PDF
15. Utility of Pathology Imagebase for standardisation of prostate cancer grading.
- Author
-
Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, and Clements M
- Subjects
- Humans, Male, Databases, Factual, Neoplasm Grading standards, Pathology, Clinical standards, Prostatic Neoplasms pathology
- Abstract
Aims: Despite efforts to standardise grading of prostate cancer, even among experts there is still a considerable variation in grading practices. In this study we describe the use of Pathology Imagebase, a novel reference image library, for setting an international standard in prostate cancer grading., Methods and Results: The International Society of Urological Pathology (ISUP) recently launched a reference image database supervised by experts. A panel of 24 international experts in prostate pathology reviewed independently microphotographs of 90 cases of prostate needle biopsies with cancer. A linear weighted kappa of 0.67 (95% confidence interval = 0.62-0.72) and consensus was reached in 50 cases. The interobserver weighted kappa varied from 0.48 to 0.89. The highest level of agreement was seen for Gleason score (GS) 3 + 3 = 6 (ISUP grade 1), while higher grades and particularly GS 4 + 3 = 7 (ISUP grade 3) showed considerable disagreement. Once a two-thirds majority was reached, images were moved automatically into a public database available for all ISUP members at www.isupweb.org. Non-members are able to access a limited number of cases., Conclusions: It is anticipated that the database will assist pathologists to calibrate their grading and, hence, decrease interobserver variability. It will also help to identify instances where definitions of grades need to be clarified., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
16. A novel technique for biobanking of large sections of radical prostatectomy specimens.
- Author
-
Lindh C, Delahunt B, Samaratunga H, Yaxley J, Gudjónsdóttir J, Clements M, Lindberg J, and Egevad L
- Subjects
- Frozen Sections methods, Humans, Male, Prostatectomy, Prostatic Neoplasms surgery, Prostatic Neoplasms diagnosis, Specimen Handling methods, Tissue Banks
- Abstract
Aims: Harvesting of unfixed tissue from radical prostatectomy specimens for research purposes is challenging. Many prostate cancers cannot be identified at gross inspection, and this tumour is notoriously multifocal and heterogeneous. We aimed to develop a technique to allow detailed topographic analysis and the sampling of a sufficient amount of tumour without jeopardising clinical reporting., Methods and Results: A custom-made double-bladed knife was utilised for cutting a 4-mm-thick horizontal section of the prostate. The slices were split into segments that were frozen in gel, cryosections were cut, and RNA integrity numbers (RINs) were analysed. Sections were cut from all blocks of 20 cases, and the cutting time was monitored. Slides were scanned, and the slices were digitally reconstructed. Cutting frozen sections of an entire slice took 79-253 min (mean 162 min). Tumour was detected in frozen sections of 85% (17/20) of cases and in 46% (72/155) of blocks. The morphological quality was determined to be excellent, and RIN values were high (mean 8.9)., Conclusions: This novel protocol for biobanking of fresh tissue from prostatectomy specimens provides sufficient tumour material for research purposes, while also enabling reporting of histopathology. The harvesting of a full tissue slice facilitates studies of tumour multifocality and heterogeneity., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
17. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.
- Author
-
Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, and Samaratunga H
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell pathology, Female, Humans, Kaplan-Meier Estimate, Kidney pathology, Kidney Neoplasms diagnosis, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Societies, Medical, World Health Organization, Young Adult, Carcinoma, Renal Cell classification, Kidney Neoplasms classification
- Abstract
Aims: In 2012, the International Society of Urological Pathology (ISUP) introduced a novel grading system for clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma. This system is incorporated into the latest World Health Organization renal tumour classification, being designated WHO/ISUP grading. This study was undertaken to compare WHO/ISUP and Fuhrman grading and to validate WHO/ISUP grading as a prognostic parameter in a series of clear cell RCC., Methods and Results: Analysis of 681 cases of ccRCC showed that 144 tumours could not be assigned a Fuhrman grade on the basis of ambiguous grading features. The application of WHO/ISUP grading resulted in a general down-grading of cases when compared with Fuhrman grading. In a sub-group of 374 cases, for which outcome data were available, 9.3% were WHO/ISUP grade 1, 50.3% were grade 2, 24.1% grade 3 and 16.3% grade 4, while the distribution of Fuhrman grades was 0.4% grade 1, 48.7% grade 2, 29.4% grade 3 and 21.5% grade 4. There were no recurrence/metastases amongst patients with WHO/ISUP grade 1 tumours and there was a significant difference in outcome for WHO/ISUP grades 2, 3 and 4. For Fuhrman grading the cancer-free survival was not significantly different for grade 2 and grade 3 tumours. On multivariate analysis WHO/ISUP grade and pT staging category were found to retain prognostic significance., Conclusions: The study demonstrates that FG cannot be applied in >20% of cases of ccRCC and the WHO/ISUP provides superior prognostic information., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
18. Pathology Imagebase-a reference image database for standardization of pathology.
- Author
-
Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, and Delahunt B
- Subjects
- Humans, Urologic Neoplasms classification, Urologic Neoplasms diagnosis, Urologic Neoplasms pathology, Urology standards, Databases, Factual, Pathology standards
- Abstract
Aims: Despite efforts to standardize histopathology practice through the development of guidelines, the interpretation of morphology is still hampered by subjectivity. We here describe Pathology Imagebase, a novel mechanism for establishing an international standard for the interpretation of pathology specimens., Methods and Results: The International Society of Urological Pathology (ISUP) established a reference image database through the input of experts in the field. Three panels were formed, one each for prostate, urinary bladder and renal pathology, consisting of 24 international experts. Each of the panel members uploaded microphotographs of cases into a non-public database. The remaining 23 experts were asked to vote from a multiple-choice menu. Prior to and while voting, panel members were unable to access the results of voting by the other experts. When a consensus level of at least two-thirds or 16 votes was reached, cases were automatically transferred to the main database. Consensus was reached in a total of 287 cases across five projects on the grading of prostate, bladder and renal cancer and the classification of renal tumours and flat lesions of the bladder. The full database is available to all ISUP members at www.isupweb.org. Non-members may access a selected number of cases., Conclusions: It is anticipated that the database will assist pathologists in calibrating their grading, and will also promote consistency in the diagnosis of difficult cases., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
19. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.
- Author
-
Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, and Egevad L
- Subjects
- Adenocarcinoma, Mucinous diagnosis, Adult, Aged, Carcinoma, Acinar Cell diagnosis, Humans, Male, Middle Aged, Neoplasm Grading, Prognosis, Prostate pathology, Prostate-Specific Antigen metabolism, Prostatectomy, Prostatic Neoplasms diagnosis, Seminal Vesicles pathology, Adenocarcinoma, Mucinous pathology, Carcinoma, Acinar Cell pathology, Prostatic Neoplasms pathology
- Abstract
Aim: The clinical significance of mucinous prostatic adenocarcinoma (PCa) remains uncertain., Methods: From 6440 cases of PCa treated by radical prostatectomy from 2009 to 2014, mucinous components of 5-100% were found in 143 (2.2%) cases., Results: The mean age was 61.4 years, mean pre-operative serum prostate-specific antigen (PSA) was 7.8 ng/ml and clinical stage category was cT1 in 81% and cT2 in 19% of cases. Cases were graded using the 2014 International Society of Urological Pathology recommendation of grading underlying architecture, and Gleason scores (GS) were 3 + 4 in 13.3%, 4 + 3 in 54.5%, 4 + 4 in 2.1%, 3 + 4 or 4 + 3 with tertiary 5 in 11.9% and 9-10 in 18.2%. The mucinous component invariably had a high-grade component. Extraprostatic extension was found in 46.8% of cases. In 21.6%, tumour volume was ≥3 cm³ and 9.7% had surgical margin positivity. Seminal vesicle involvement was found in 6.9%. In 73 cases the mucinous component was >25%, and when cases were divided on the basis of the area of mucin present (≤25 versus >25%) there was no significant difference between clinical or pathological features. Similar findings were achieved when cases were compared with grade-matched non-mucinous carcinoma controls. The 5-year biochemical recurrence rates for mucinous versus non-mucinous cancer were 12.5 versus 17% (P = 0.15)., Conclusion: PCa with mucinous components is often high grade; however, the prognosis appears to be similar to non-mucinous cancers of similar GS., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
20. UICC drops the ball in the 8th edition TNM staging of urological cancers.
- Author
-
Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, Cheville J, Kristiansen G, Corbishley C, and Berney DM
- Subjects
- Humans, Societies, Medical, Medical Oncology standards, Neoplasm Staging standards, Practice Guidelines as Topic standards, Urologic Neoplasms classification, Urologic Neoplasms pathology
- Published
- 2017
- Full Text
- View/download PDF
21. Reply: 'A plea for greater standardization in intraductal carcinoma of the prostate -greater standardization requires greater evidence': let's use the available evidence.
- Author
-
Varma M, Egevad L, Delahunt B, and Kristiansen G
- Subjects
- Humans, Male, Reference Standards, Carcinoma, Intraductal, Noninfiltrating, Prostate
- Published
- 2017
- Full Text
- View/download PDF
22. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel.
- Author
-
Williamson SR, Delahunt B, Magi-Galluzzi C, Algaba F, Egevad L, Ulbright TM, Tickoo SK, Srigley JR, Epstein JI, and Berney DM
- Subjects
- Humans, Male, Neoplasms, Germ Cell and Embryonal classification, Testicular Neoplasms classification
- Abstract
Since the last World Health Organization (WHO) classification scheme for tumours of the urinary tract and male genital organs, there have been a number of advances in the understanding, classification, immunohistochemistry and genetics of testicular germ cell tumours. The updated 2016 draft classification was discussed at an International Society of Urological Pathology Consultation on Testicular and Penile Cancer. This review addresses the main updates to germ cell tumour classification. Major changes include a pathogenetically derived classification using germ cell neoplasia in situ (GCNIS) as a new name for the precursor lesion, and the distinction of prepubertal tumours (non-GCNIS-derived) from postpubertal-type tumours (GCNIS-derived), acknowledging the existence of rare benign prepubertal-type teratomas in the postpubertal testis. Spermatocytic tumour is adopted as a replacement for spermatocytic seminoma, to avoid potential confusion with the unrelated usual seminoma. The spectrum of trophoblastic tumours arising in the setting of testicular germ cell tumour continues to expand, to include epithelioid and placental site trophoblastic tumours analogous to those of the gynaecological tract. Currently, reporting of anaplasia (seminoma or spermatocytic tumour) or immaturity (teratoma) is not required, as these do not have demonstrable prognostic importance. In contrast, overgrowth of a teratomatous component (somatic-type malignancy) and sarcomatous change in spermatocytic tumour indicate more aggressive behaviour, and should be reported., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
23. Reporting intraductal carcinoma of the prostate: a plea for greater standardization.
- Author
-
Varma M, Egevad L, Delahunt B, and Kristiansen G
- Subjects
- Humans, Male, Adenocarcinoma diagnosis, Carcinoma, Ductal diagnosis, Pathology, Clinical standards, Prostatic Neoplasms diagnosis
- Published
- 2017
- Full Text
- View/download PDF
24. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists.
- Author
-
Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Compérat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, and van Leenders GJ
- Subjects
- Humans, Male, Observer Variation, Pathologists, Pathology, Clinical, Adenocarcinoma pathology, Neoplasm Grading, Prostatic Neoplasms pathology
- Abstract
Aims: To assess the interobserver reproducibility of individual Gleason grade 4 growth patterns., Methods and Results: Twenty-three genitourinary pathologists participated in the evaluation of 60 selected high-magnification photographs. The selection included 10 cases of Gleason grade 3, 40 of Gleason grade 4 (10 per growth pattern), and 10 of Gleason grade 5. Participants were asked to select a single predominant Gleason grade per case (3, 4, or 5), and to indicate the predominant Gleason grade 4 growth pattern, if present. 'Consensus' was defined as at least 80% agreement, and 'favoured' as 60-80% agreement. Consensus on Gleason grading was reached in 47 of 60 (78%) cases, 35 of which were assigned to grade 4. In the 13 non-consensus cases, ill-formed (6/13, 46%) and fused (7/13, 54%) patterns were involved in the disagreement. Among the 20 cases where at least one pathologist assigned the ill-formed growth pattern, none (0%, 0/20) reached consensus. Consensus for fused, cribriform and glomeruloid glands was reached in 2%, 23% and 38% of cases, respectively. In nine of 35 (26%) consensus Gleason grade 4 cases, participants disagreed on the growth pattern. Six of these were characterized by large epithelial proliferations with delicate intervening fibrovascular cores, which were alternatively given the designation fused or cribriform growth pattern ('complex fused')., Conclusions: Consensus on Gleason grade 4 growth pattern was predominantly reached on cribriform and glomeruloid patterns, but rarely on ill-formed and fused glands. The complex fused glands seem to constitute a borderline pattern of unknown prognostic significance on which a consensus could not be reached., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
25. Reply: Gleason and Fuhrman no longer make the grade.
- Author
-
Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, and Srigley JR
- Subjects
- Humans, Prostatic Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms
- Published
- 2016
- Full Text
- View/download PDF
26. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation.
- Author
-
Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Ferguson P, and Nacey JN
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Carcinoma, Transitional Cell pathology, Cell Dedifferentiation, Female, Humans, Immunohistochemistry, Male, Middle Aged, Carcinoma, Giant Cell pathology, Urinary Bladder Neoplasms pathology
- Abstract
Aims: Vesical pleomorphic giant cell carcinoma (PGCC) is a variant of urothelial carcinoma (UC) characterized by highly pleomorphic tumour with giant cells. Fewer than 10 cases have been reported, and our aim was to determine the clinical and pathological features of a series of tumours from a specialized uropathology laboratory., Methods and Results: Thirteen cases of PGCC of the bladder were identified. There were nine males and four females, ranging in age from 53 to 92 years (mean 72 years). Associated conventional high-grade UC was seen in eight cases, while three cases also had micropapillary UC and one plasmacytoid UC. UC in situ (CIS) was present in five cases and occasional bizarre cells were seen in both UC and CIS. The proportion of PGCC present varied from 40% to 100% of tumour. Immunostaining performed on 10 cases showed uniform positivity for CK 8/18 and AE1/AE3, while most tumours were positive for CK7, CK20, uroplakin III and GATA binding protein 3 (GATA3). β-human chorionic gonadotrophin (β-hCG) was negative. Of 10 patients with follow-up, five died within 1 year and four are alive with tumour., Conclusions: The association of PGCC with UC and an overlap in immunoexpression suggests that PGCC represents an extreme form of UC de-differentiation., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
27. Gleason and Fuhrman no longer make the grade.
- Author
-
Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, and Srigley JR
- Subjects
- Humans, Male, Neoplasm Grading standards, Adenocarcinoma pathology, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology, Neoplasm Grading methods, Prostatic Neoplasms pathology
- Abstract
Grading is an important prognostic parameter for prostate adenocarcinoma and renal cell carcinoma (RCC); however, the most frequently used classifications fail to account for advances in our understanding of the diagnostic features, classification and/or behaviour of these tumours. In 2005 and 2014, the International Society of Urological Pathology (ISUP) proposed changes to Gleason scoring with the adoption of the ISUP grading for prostate cancer in 2014 (grade 1, score 3 + 3; grade 2, score 3 + 4; grade 3, score 4 + 3; grade 4, score 8; grade 5, score 9-10). Internationally the Fuhrman grading system is widely employed despite criticisms related to its application, validity, and reproducibility. In 2012, the ISUP established a grading system for RCC (grade 1, the nucleolus is not seen or is inconspicuous and basophilic at ×400 magnification; grade 2, nucleoli are eosinophilic and clearly visible at ×400 magnification; grade 3, nucleoli are clearly visible at ×100 magnification; grade 4, tumours show extreme pleomorphism or rhabdoid and/or sarcomatoid morphology). This grading has been validated for clear cell RCC and papillary RCC. It was further recommended that chromophobe RCC not be graded. For other morphotypes of RCC, ISUP grading has not been validated as a prognostic parameter, but can be used for descriptive purposes., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
28. Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists.
- Author
-
Berney DM, Algaba F, Amin M, Delahunt B, Compérat E, Epstein JI, Humphrey P, Idrees M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Oliva E, Srigley J, Reuter VE, Trpkov K, Ulbright TM, Varma M, Verrill C, Young RH, Zhou M, and Egevad L
- Subjects
- Consensus, Europe, Expert Testimony, Humans, Immunohistochemistry statistics & numerical data, Male, Neoplasm Invasiveness pathology, Neoplasm Staging methods, Neoplasms, Germ Cell and Embryonal metabolism, Neoplasms, Germ Cell and Embryonal surgery, Observer Variation, Orchiectomy, Specimen Handling methods, Surveys and Questionnaires, Testicular Neoplasms metabolism, Testicular Neoplasms surgery, Neoplasms, Germ Cell and Embryonal pathology, Testicular Neoplasms pathology
- Abstract
Aims: The handling and reporting of testicular tumours is difficult due to their rarity., Methods and Results: A survey developed by the European Network of Uro-Pathology (ENUP) and sent to its members and experts to assess the evaluation of testicular germ cell tumours. Twenty-five experts and 225 ENUP members replied. Areas of disagreement included immaturity in teratomas, reported by 32% of experts but 68% of ENUP. Although the presence of rete testis invasion was reported widely, the distinction between pagetoid and stromal invasion was made by 96% of experts but only 63% of ENUP. Immunohistochemistry was used in more than 50% of cases by 68% of ENUP and 12% of experts. Staging revealed the greatest areas of disagreement. Invasion of the tunica vaginalis without vascular invasion was interpreted as T1 by 52% of experts and 67% of ENUP, but T2 by the remainder. Tumour invading the hilar adipose tissue adjacent to the epididymis without vascular invasion was interpreted as T1: 40% of experts, 43% of ENUP; T2: 36% of experts, 30% of ENUP; and T3: 24% of experts, 27% of ENUP., Conclusions: There is remarkable consensus in many areas of testicular pathology. Significant areas of disagreement included staging and reporting of histological types, both of which have the potential to impact on therapy., Competing Interests: Statement. No conflicts of interest are declared., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
29. Effective maybe, but is it cost-effective? A reply.
- Author
-
Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN, and Delahunt B
- Subjects
- Humans, Male, Adenocarcinoma secondary, Adenocarcinoma surgery, Lymph Node Excision methods, Lymphatic Metastasis diagnosis, Neoplasm Micrometastasis diagnosis, Prostatectomy methods, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Published
- 2014
- Full Text
- View/download PDF
30. Percutaneous renal tumour biopsy.
- Author
-
Delahunt B, Samaratunga H, Martignoni G, Srigley JR, Evans AJ, and Brunelli M
- Subjects
- Adenoma, Oxyphilic diagnosis, Adenoma, Oxyphilic pathology, Biopsy, Needle adverse effects, Biopsy, Needle instrumentation, Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell pathology, Humans, Reproducibility of Results, Biopsy, Needle methods, Kidney pathology, Kidney Neoplasms diagnosis, Kidney Neoplasms pathology
- Abstract
The use of percutaneous renal tumour biopsy (RTB) as a diagnostic tool for the histological characterization of renal masses has increased dramatically within the last 30 years. This increased utilization has paralleled advances in imaging techniques and an evolving knowledge of the clinical value of nephron sparing surgery. Improved biopsy techniques using image guidance, coupled with the use of smaller gauge needles has led to a decrease in complication rates. Reports from series containing a large number of cases have shown the non-diagnostic rate of RTB to range from 4% to 21%. Re-biopsy has been shown to reduce this rate, while the use of molecular markers further improves diagnostic sensitivity. In parallel with refinements of the biopsy procedure, there has been a rapid expansion in our understanding of the complexity of renal cell neoplasia. The 2013 Vancouver Classification is the current classification for renal tumours, and contains five additional entities recognized as novel forms of renal malignancy. The diagnosis of tumour morphotype on RTB is usually achievable on routine histology; however, immunohistochemical studies may be of assistance in difficult cases. The morphology of the main tumour subtypes, based upon the Vancouver Classification, is described and differentiating features are discussed., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
31. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.
- Author
-
Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, and Egevad L
- Subjects
- Humans, Male, Medical Oncology standards, Observer Variation, Urology standards, Carcinoma, Ductal diagnosis, Prostatic Neoplasms diagnosis
- Abstract
Aims: Ductal adenocarcinoma of the prostate (DAC) is clinically important, because its behaviour may differ from that of acinar adenocarcinoma. Our aims were to investigate the interobserver variability of this diagnosis among experts in uropathology and to define diagnostic criteria., Methods and Results: Photomicrographs of 21 carcinomas with ductal features were distributed among 20 genitourinary pathologists from eight countries. DAC was diagnosed by 18 observers (mean 13.2 cases, range 6-19). In 11 (52%) cases, a 2/3 consensus was reached for a diagnosis of DAC, and in five (24%) there was consensus against. In DAC, the respondents reported papillary architecture (86%), stratification of nuclei (82%), high-grade nuclear features (54%), tall columnar epithelium (53%), elongated nuclei (52%), cribriform architecture (40%), and necrosis (7%). The most important diagnostic feature reported for DAC was papillary architecture (59%), whereas nuclear and cellular features were considered to be most important in only 2-11% of cases. The most common differential diagnoses were intraductal prostate cancer (52%), high-grade PIN (37%), and acinar adenocarcinoma (17%). The most common reason for not diagnosing DAC was lack of typical architecture (33%)., Conclusions: Papillary architecture was the most useful diagnostic feature of DAC, and nuclear and cellular features were considered to be less important., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
32. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases.
- Author
-
Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN, and Delahunt B
- Subjects
- Adenocarcinoma pathology, Humans, Lymphatic Metastasis pathology, Male, Neoplasm Grading, Neoplasm Micrometastasis pathology, Pelvis surgery, Prognosis, Adenocarcinoma secondary, Adenocarcinoma surgery, Lymph Node Excision methods, Lymphatic Metastasis diagnosis, Neoplasm Micrometastasis diagnosis, Prostatectomy methods, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Abstract
Aims: The detection of lymph node metastases has prognostic and therapeutic implications for patients undergoing radical prostatectomy for prostate cancer. Macroscopic identification of pelvic lymph nodes in surgical lymphadenectomy specimens can be difficult, with a potential for incomplete submission of lymph nodes for microscopic examination. This study was undertaken to determine whether complete sampling of lymphadenectomy specimens would improve the detection of metastatic disease in patients undergoing radical prostatectomy., Methods and Results: We examined 109 pelvic lymphadenectomies accompanying radical prostatectomy specimens to assess the benefit of complete submission of the lymph node packets to detect extra lymph nodes and metastatic disease. We found that blocking the residual tissue, after all palpable lymph nodes had been identified, increased the mean number of lymph nodes from 3.8 to 10.8, with an average of 0.84 macroscopically undetectable nodes being recovered per block submitted. Metastatic prostate cancer was identified in eight cases, one of which had cancer in an impalpable lymph node only., Conclusions: Submission of all pelvic lymphadenectomy tissue for histological examination improves the yield of lymph nodes and the detection of metastatic prostate cancer., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
33. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting.
- Author
-
Kench JG, Delahunt B, Griffiths DF, Humphrey PA, McGowan T, Trpkov K, Varma M, Wheeler TM, and Srigley JR
- Subjects
- Adenocarcinoma surgery, Australasia, Consensus, Humans, International Cooperation, Male, Prognosis, Prostatic Neoplasms surgery, United Kingdom, United States, Adenocarcinoma pathology, Databases as Topic, Medical Records standards, Pathology, Surgical standards, Prostatectomy, Prostatic Neoplasms pathology
- Abstract
This project was designed to harmonise the Royal College of Pathologists, College of American Pathologists and Royal College of Pathologists of Australasia datasets, checklists and structured reporting protocols for examination of radical prostatectomy specimens, with the aim of producing a common, internationally agreed, evidence-based dataset for prostate cancer reporting. The International Collaboration on Cancer Reporting prostate cancer expert review panel analysed the three existing datasets, identifying concordant items and classified these data elements as 'required' (mandatory) or 'recommended' (non-mandatory), on the basis of the published literature up to August 2011. Required elements were defined as those that have agreed evidentiary support at NHMRC level III-2 or above. Consensus response values were formulated for each item. Twelve concordant pathology data elements were identified, and, on review, all but one were included as required elements for tumour staging, grading, or prediction of prognosis. There was minor discordance between the three existing datasets for another eight items, with two of these being added to the required data set. Another 11 elements with a lesser level of evidentiary support were included in the recommended dataset. This process was found to be an efficient method for producing an evidence-based dataset for prostate cancer. Such internationally agreed datasets should facilitate meaningful comparison of benchmarking data, epidemiological studies, and clinical trials., (© 2012 Blackwell Publishing Limited.)
- Published
- 2013
- Full Text
- View/download PDF
34. Gleason grading: past, present and future.
- Author
-
Delahunt B, Miller RJ, Srigley JR, Evans AJ, and Samaratunga H
- Subjects
- Humans, Male, Neoplasm Grading methods, Prognosis, Prostate pathology, Prostatic Neoplasms classification, Prostatic Neoplasms diagnosis, Reproducibility of Results, Prostatic Neoplasms pathology
- Abstract
In 1966 Donald Gleason developed his grading and scoring system for prostatic adenocarcinoma. This classification was refined in 1974 and gained almost universal acceptance, being classified as a category 1 prognostic parameter by the College of American Pathologists. Modifications to the classification were recommended at a conference convened by the International Society of Urological Pathology (ISUP) in 2005. This modified classification has resulted in a significant upgrading of tumours, although some studies have shown a greater concordance between needle biopsy and radical prostatectomy scores when compared to classical Gleason (CG) grading. The ISUP consensus conference recommended that for needle biopsies higher tertiary patterns should be incorporated into the final Gleason score, and this has been correlated with biochemical failure, tumour volume and mortality. Recently the validity of including cribriform glands as a component of Gleason pattern 3 has been questioned and it has been recommended that all tumours showing cribriform architecture should be classified as Gleason pattern 4. The recommendations arising from the 2005 Consensus Conference were largely unsupported by validating data, yet this new grading system has achieved widespread usage. It is unfortunate that recent suggestions for further modification are similarly lacking in supporting evidence. In view of this it is recommended that the Modified Gleason Scoring Classification should continue to be utilized in its original (2005) format and that any future alterations should be implemented only when mandated by tumour-related outcome studies., (© 2011 Blackwell Publishing Limited.)
- Published
- 2012
- Full Text
- View/download PDF
35. Therapy-associated effects in the prostate gland.
- Author
-
Srigley JR, Delahunt B, and Evans AJ
- Subjects
- Biomarkers, Tumor metabolism, Humans, Male, Prostate drug effects, Prostate radiation effects, Prostate surgery, Prostatectomy, Prostatic Hyperplasia pathology, Prostatic Hyperplasia therapy, Prostatic Neoplasms pathology, Prostate pathology, Prostatic Neoplasms therapy
- Abstract
Diverse therapies are used to treat both benign prostatic hyperplasia and adenocarcinoma. Transurethral resection, a common surgical procedure, may give rise to characteristic necrobiotic granulomas that manifest in subsequent pathology samples. Radiation and hormone therapy have traditionally been used in prostatic adenocarcinoma. Morphological effects are often identified in needle biopsy specimens, transurethral resectates, and radical prostatectomy specimens. A range of histological changes are noted in the non-neoplastic prostate tissue, as well as in the pre-neoplastic and carcinomatous areas. Other ablative therapies, such as cryotherapy, and emerging focal therapies, including high-intensity focused ultrasound, photodynamic therapy, and interstitial laser thermotherapy, may have morphological effects on prostate tissue. It is important for the pathologist to be aware of the spectrum of histological changes affecting the prostate gland post-therapy. The treatment effects may obscure residual carcinoma, and make measurements of tumour extent and stage difficult. Furthermore, some therapies can profoundly alter the neoplastic glands to such an extent that Gleason scoring is no longer valid. As new therapies are developed for prostate cancer, it is important to document their effects on benign and malignant prostate tissue and to understand possible implications for traditional prognostic factors, especially Gleason grade., (© 2011 Blackwell Publishing Limited.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.